Biocryst Pharmaceuticals Inc BCRX Stock Forecast
AI-powered price prediction and analysis for Biocryst Pharmaceuticals Inc ยท Updated Sep 21, 2026
See BCRX's Exact Price Target
Create a free account and follow this stock to unlock its full AI forecast โ 3 stocks free.
Sign Up Free with GooglePrice Chart
Key Statistics
About Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc (BCRX) operates in the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. .
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Latest News
Where BCRX sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | Ticker | AI Signal | Market Cap | P/E |
|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc | BCRX | โโ% | $2.24B | -x |
| Amgen Inc | AMGN | โโ% | $212.55B | 24.3x |
| Gilead Sciences, Inc. | GILD | โโ% | $186.69B | -x |
| Moderna, Inc. | MRNA | โโ% | $69.04B | -x |
| Argenx Se | ARGX | โโ% | $61.15B | -x |
| Revolution Medicines, Inc. | RVMD | โโ% | $40.93B | -x |
| Biogen Inc. | BIIB | โโ% | $32.34B | 23.6x |
| Biontech Se | BNTX | โโ% | $24.78B | -x |
| Mesoblast Ltd | MESO | โโ% | $20.08B | -x |
| Neurocrine Biosciences Inc | NBIX | โโ% | $14.63B | 20.7x |
| Exelixis, Inc. | EXEL | โโ% | $14.18B | -x |
| Halozyme Therapeutics, Inc. | HALO | โโ% | $12.65B | 30.6x |
| Bio-Techne Corp | TECH | โโ% | $11.35B | 62.4x |
| Twist Bioscience Corp | TWST | โโ% | $10.47B | -x |
| Repligen Corp | RGEN | โโ% | $9.98B | 240.3x |
| Krystal Biotech, Inc. | KRYS | โโ% | $9.88B | 40.9x |
| Kymera Therapeutics, Inc. | KYMR | โโ% | $9.78B | -x |
| Qiagen N.V. | QGEN | โโ% | $9.40B | -x |
| Immunitybio, Inc. | IBRX | โโ% | $8.96B | -x |
| Vaxcyte, Inc. | PCVX | โโ% | $8.65B | -x |
| Immunovant, Inc. | IMVT | โโ% | $7.68B | -x |
| Cg Oncology, Inc. | CGON | โโ% | $6.94B | -x |
| Scholar Rock Holding โฆ | SRRK | โโ% | $5.68B | -x |
| Crispr Therapeutics Ag | CRSP | โโ% | $5.64B | -x |
| Iovance Biotherapeutics, Inc. | IOVA | โโ% | $4.62B | -x |
| Adaptive Biotechnologies Corp | ADPT | โโ% | $4.45B | -x |
| Relay Therapeutics, Inc. | RLAY | โโ% | $4.13B | -x |
| Dbv Technologies S.A. | DBVT | โโ% | $3.58B | -x |
| Tarsus Pharmaceuticals, Inc. | TARS | โโ% | $3.43B | -x |
| Denali Therapeutics Inc. | DNLI | โโ% | $3.27B | -x |
| Beam Therapeutics Inc. | BEAM | โโ% | $2.61B | -x |
| Scinai Immunotherapeutics Ltd. | SCNI | โโ% | $2.16B | -x |
| Adma Biologics, Inc. | ADMA | โโ% | $2.13B | 12.6x |
| Recursion Pharmaceuticals, Inc. | RXRX | โโ% | $2.05B | -x |
| Vericel Corp | VCEL | โโ% | $2.05B | 84.6x |
| Kodiak Sciences Inc. | KOD | โโ% | $2.04B | -x |
| Alvotech | ALVO | โโ% | $1.83B | -x |
| Vir Biotechnology, Inc. | VIR | โโ% | $1.79B | -x |
| Hemab Therapeutics Holdings, โฆ | COAG | โโ% | $1.77B | -x |
| Novavax Inc | NVAX | โโ% | $1.67B | -x |
| Immunocore Holdings Plc | IMCR | โโ% | $1.66B | -x |
| Taysha Gene Therapies, โฆ | TSHA | โโ% | $1.64B | -x |
| Cullinan Therapeutics, Inc. | CGEM | โโ% | $1.37B | -x |
| Vor Biopharma Inc. | VOR | โโ% | $1.27B | -x |
| Meiragtx Holdings Plc | MGTX | โโ% | $1.26B | 15.9x |
| Maze Therapeutics, Inc. | MAZE | โโ% | $1.24B | -x |
| Replimune Group, Inc. | REPL | โโ% | $1.23B | -x |
| Zura Bio Ltd | JATT | โโ% | $1.17B | -x |
| Immatics N.V. | IMTX | โโ% | $1.17B | -x |
| Valneva Se | VALN | โโ% | $1.14B | -x |
| Odyssey Therapeutics, Inc. | ODTX | โโ% | $1.11B | -x |
| Monte Rosa Therapeutics, โฆ | GLUE | โโ% | $1.05B | -x |
| Solid Biosciences Inc. | SLDB | โโ% | $955M | -x |
| Sana Biotechnology, Inc. | SANA | โโ% | $928M | -x |
| Candel Therapeutics, Inc. | CADL | โโ% | $858M | -x |
| 4d Molecular Therapeutics, โฆ | FDMT | โโ% | $841M | -x |
| Aura Biosciences, Inc. | AURA | โโ% | $660M | -x |
| Allogene Therapeutics, Inc. | ALLO | โโ% | $584M | -x |
| Prime Medicine, Inc. | PRME | โโ% | $566M | -x |
| Ginkgo Bioworks Holdings, โฆ | DNA | โโ% | $537M | -x |
FAQ
-
Is Biocryst Pharmaceuticals Inc a good stock to buy?
Our AI analyzes Biocryst Pharmaceuticals Inc daily. Check the signal above for the latest recommendation. Always do your own research before investing.
-
How accurate are Biocryst Pharmaceuticals Inc predictions?
A per-ticker accuracy statistic for BCRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
-
How often are forecasts updated?
Biocryst Pharmaceuticals Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.
Ready to invest smarter?
Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Biocryst Pharmaceuticals Inc?
View full institutional-grade analysis on Intratio โAI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.